CytoMed Therapeutics Limited Ordinary Shares (GDTC) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $1.08
• Market Cap: $22.53M
• EPS: $-0.25
• 52-Week High: $3.68
• 52-Week Low: $0.73

About CytoMed Therapeutics Limited Ordinary Shares

CytoMed Therapeutics Limited (GDTC) is a pioneering pre-clinical biopharmaceutical firm located in Singapore, focusing on the development of innovative cell-based immunotherapies to treat various forms of cancer. The company harnesses advanced technology and research to create proprietary therapeutic candidates that aim to fulfill significant unmet medical needs in oncology. With a robust pipeline and a commitment to leveraging cutting-edge science, CytoMed is strategically positioned in the ...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for CytoMed Therapeutics Limited Ordinary Shares and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does GDTC pay dividends?

CytoMed Therapeutics Limited Ordinary Shares (GDTC) does not currently pay a regular dividend.

What is GDTC's market cap?

CytoMed Therapeutics Limited Ordinary Shares (GDTC) has a market capitalization of $22.53M with a current stock price of $1.08.